Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | WDR5 | P61964 | 4/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198175 | 1.00 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL861991 | 0.94 | ALDH1A1 (0.64) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL14464189 | 0.92 | ALDH1A1 (0.79) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| Methylpiperazine SCHEMBL5742882 | 0.92 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL9300572 | 0.88 | ALDH1A1 (0.58) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL10036446 | 0.88 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL30306129 | 0.87 | ALDH1A1 (0.57) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL22471238 | 0.87 | ALDH1A1 (0.57) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL10128069 | 0.87 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2AMAPTTHRB | |
| SCHEMBL4921368 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNAKMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4153576-A1 | NOTCH INHIBITORS AND USES THEREOF | StemSynergy Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2004032882-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| CN-1487927-A | Diaminothiazoles | - | 2004-04-07 | — | — | CN | disclosed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
| EP-1130016-A1 | THIOCARBAMIC ACID DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | ALDH1A1 1009/4885LMNA 2122/4885KMT2A 634/4885 |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | ALDH1A1 3543/4885LMNA 2338/4885KMT2A 2583/4885 |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | ALDH1A1 370/4885LMNA 4524/4885KMT2A 3699/4885 |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | ALDH1A1 2288/4885LMNA 3567/4885KMT2A 1979/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | ALDH1A1 2468/4885LMNA 1851/4885KMT2A 3095/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | ALDH1A1 1009/4885LMNA 2122/4885KMT2A 634/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | ALDH1A1 858/4885LMNA 1526/4885KMT2A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.